SPP1 and non-small cell lung carcinoma: CONCLUSION: This study establishes AICD as a clinically relevant metabolic cell death mechanism in NSCLC and identifies SLC7A5, SLC2A1, CAV1, and SPP1 as potential prognostic biomarkers and therapeutic targets.